New Approach for Risk Estimation Algorithms of Negativeness Detection with Modelling Supervised Machine Learning Techniques.

Journal: Disease markers
Published Date:

Abstract

gene testing is a difficult, expensive, and time-consuming test which requires excessive work load. The identification of the gene mutations is significantly important in the selection of treatment and the risk of secondary cancer. We aimed to develop an algorithm considering all the clinical, demographic, and genetic features of patients for identifying the negativity in the present study. An experimental dataset was created with the collection of the all clinical, demographic, and genetic features of breast cancer patients for 20 years. This dataset consisted of 125 features of 2070 high-risk breast cancer patients. All data were numeralized and normalized for detection of the negativity in the machine learning algorithm. The performance of the algorithm was identified by studying the machine learning model with the test data. nearest neighbours (KNN) and decision tree (DT) accuracy rates of 9 features involving Dataset 2 were found to be the most effective. The removal of the unnecessary data in the dataset by reducing the number of features was shown to increase the accuracy rate of algorithm compared with the DT. negativity was identified without performing the gene test with 92.88% accuracy within minutes in high-risk breast cancer patients with this algorithm, and the test associated result waiting stress, time, and money loss were prevented. That algorithm is suggested be useful in fast performing of the treatment plans of patients and accurately in addition to speeding up the clinical practice.

Authors

  • Hulya Yazici
    Istanbul University, Oncology Institute, Department of Basic Oncology, Division of Cancer Genetics, 34093 Fatih, Istanbul, Turkey.
  • Demet Akdeniz Odemis
    Istanbul University, Oncology Institute, Department of Basic Oncology, Division of Cancer Genetics, 34093 Fatih, Istanbul, Turkey.
  • Dogukan Aksu
    Istanbul University-Cerrahpasa, Engineering Faculty, Computer Engineering Department, 34320 Avcilar, Istanbul, Turkey.
  • Ozge Sukruoglu Erdogan
    Istanbul University, Oncology Institute, Department of Basic Oncology, Division of Cancer Genetics, 34093 Fatih, Istanbul, Turkey.
  • Seref Bugra Tuncer
    Istanbul University, Oncology Institute, Department of Basic Oncology, Division of Cancer Genetics, 34093 Fatih, Istanbul, Turkey.
  • Mukaddes Avsar
    Istanbul University, Oncology Institute, Department of Basic Oncology, Division of Cancer Genetics, 34093 Fatih, Istanbul, Turkey.
  • Seda Kilic
    Istanbul University, Oncology Institute, Department of Basic Oncology, Division of Cancer Genetics, 34093 Fatih, Istanbul, Turkey.
  • Gozde Kuru Turkcan
    Istanbul University, Oncology Institute, Department of Basic Oncology, Division of Cancer Genetics, 34093 Fatih, Istanbul, Turkey.
  • Betul Celik
    Istanbul University, Oncology Institute, Department of Basic Oncology, Division of Cancer Genetics, 34093 Fatih, Istanbul, Turkey.
  • Muhammed Ali Aydin
    Istanbul University-Cerrahpasa, Engineering Faculty, Computer Engineering Department, 34320 Avcilar, Istanbul, Turkey.